

5-1-2011

A population-based study of dystrophin mutations in Canada

Jean Mah
University of Calgary

Kathryn Selby
The University of British Columbia

Craig Campbell
Western University

Amelie Nadeau
CHU Sainte-Justine - Le Centre Hospitalier Universitaire Mère-Enfant

Mark Tarnopolsky
McMaster University Medical Centre

See next page for additional authors

Follow this and additional works at: <https://ir.lib.uwo.ca/paedpub>

Citation of this paper:

Mah, Jean; Selby, Kathryn; Campbell, Craig; Nadeau, Amelie; Tarnopolsky, Mark; McCormick, Anna; Dooley, Joseph; and Kolski, Hanna, "A population-based study of dystrophin mutations in Canada" (2011).

Paediatrics Publications. 1488.

<https://ir.lib.uwo.ca/paedpub/1488>

Authors

Jean Mah, Kathryn Selby, Craig Campbell, Amelie Nadeau, Mark Tarnopolsky, Anna McCormick, Joseph Dooley, and Hanna Kolski

A Population-Based Study of Dystrophin Mutations in Canada

Jean K. Mah, Kathryn Selby, Craig Campbell, Amelie Nadeau, Mark Tarnopolsky, Anna McCormick, Joseph M. Dooley, Hanna Kolski, Andrew J. Skalsky, R. Garth Smith, David Buckley, Peter N. Ray, Grace Yoon, on behalf of the Canadian Paediatric Neuromuscular Group

ABSTRACT: Introduction: We carried out a population-based study of dystrophin mutations in patients followed by members of the Canadian Paediatric Neuromuscular Group (CPNG) over a ten-year period. **Objectives:** We aimed to describe the changes in diagnostic testing for dystrophinopathy and to determine the frequency of dystrophin mutations from 2000 to 2009. **Methods:** De-identified data containing the clinical phenotypes, diagnostic methods, and mutational reports from dystrophinopathy patients followed by CPNG centres from January 2000 to December 2009 were analyzed using descriptive statistics. **Results:** 773 patients had a confirmed diagnosis of dystrophinopathy based on genetic testing (97%), muscle biopsy (2%), or family history (1%). 573 (74%) had complete deletion/duplication analysis of all 79 exons or whole gene sequencing, resulting in 366 (64%) deletions, 64 (11%) duplications, and 143 (25%) point mutations. The percentage of patients who were diagnosed using currently accepted genetic testing methods varied across Canada, with a mean of 63% (SD 23). 246 (43%) mutations involved exons 45 to 53. The top ten deletions (n=147, 26%) were exons 45–47, 45–48, 45, 45–50, 45–55, 51, 45–49, 45–52, 49–50, and 46–47. 169 (29%) mutations involved exons 2 to 20. The most common duplications (n=29, 5.1%) were exons 2, 2–7, 2–17, 3–7, 8–11, 10, 10–11, and 12. **Conclusion:** This is the most comprehensive report of dystrophin mutations in Canada. Consensus guidelines regarding the diagnostic approach to dystrophinopathy will hopefully reduce the geographical variation in mutation detection rates in the coming decade.

RÉSUMÉ: Étude de population sur les mutations de la dystrophine au Canada. Contexte : Nous avons effectué une étude de population sur les mutations du gène de la dystrophine chez des patients suivis par des membres du Canadian Paediatric Neuromuscular Group (CPNG) au cours d'une période de 10 ans. **Objectifs :** Notre but était de décrire l'évolution des tests diagnostiques des dystrophinopathies et de déterminer la fréquence des mutations du gène de la dystrophine de 2000 à 2009. **Méthode :** Nous avons analysé par des méthodes statistiques descriptives des données anonymisées, soit le phénotype clinique, les méthodes diagnostiques et l'identification de la mutation, chez des patients atteints de dystrophinopathies suivis dans des centres du CPNG de janvier 2000 à décembre 2009. **Résultats :** Un diagnostic de dystrophinopathie, confirmé par un test génétique (97%), une biopsie musculaire (2%) ou une histoire familiale (1%), a été posé chez 773 patients. Chez 573 patients (74%) une analyse complète des délétions/duplications des 79 exons ou un séquençage complet du gène a été effectué. Nous avons identifié des délétions chez 366 (64%) patients, des duplications chez 64 (11%) et des mutations ponctuelles chez 143 (25%). Le pourcentage de patients chez qui le diagnostic de la maladie a été posé au moyen d'un test génétique dont la méthode de laboratoire est actuellement reconnue, était variable à travers le Canada, soit chez 63% des patients (ET 23). Deux cent quarante-six (43%) des mutations étaient situées dans les exons 45 à 53. Les 10 délétions les plus fréquentes (n = 147), soit 26%, étaient situées dans les exons 45-47, 45-48, 45, 45-50, 45-55, 51, 45-49, 45-52, 49-50 et 46-47. Cent soixante-neuf mutations (29%) étaient situées dans les exons 2 à 20. Les duplications les plus fréquentes (n = 29), soit 5,1% étaient situées dans les exons 2, 2-7, 2-17, 3-7, 8-11, 10, 10-11 et 12. **Conclusion :** Il s'agit du compte rendu le plus complet sur les mutations du gène de la dystrophine au Canada. D'ici une dizaine d'années, des lignes directrices de consensus concernant l'approche diagnostique des dystrophinopathies réduiront sans doute les disparités géographiques dans le taux de détection des mutations du gène de la dystrophine.

Can. J. Neurol. Sci. 2011; 38: 465-474

From the Division of Neurology (JKM), Department of Paediatrics, University of Calgary, Alberta Children's Hospital, Calgary; Division of Neurology (HK), Department of Paediatrics, University of Alberta, Stollery Children's Hospital, Edmonton, AB; Division of Neurology (KS), Department of Paediatrics, University of British Columbia, BC Children's Hospital, Vancouver, BC; Division of Paediatric Neurology (JMD), Dalhousie University, the IWK Health Centre, Halifax, NS; Division of Rehabilitative Medicine (AJS), Department of Paediatrics, University of Manitoba, Winnipeg, MB; Department of Paediatrics (DB), Memorial University, Health Sciences Centre, St. John's, NL; Department of Neurology (AN), CHU Sainte-Justine, Montreal, QC; Division of Neuromuscular and Neurometabolic Disorders (MT), Department of Paediatrics and Medicine, McMaster Children's Hospital, McMaster University Medical Centre, Hamilton; Departments of Paediatrics (CC), Clinical Neurological Sciences and Epidemiology, University of Western Ontario, London Health Sciences Centre, London; Division of Physical Medicine and Rehabilitation Medicine (AM), Department of Medicine and Paediatrics, Children's Hospital of Eastern Ontario, Ottawa; Divisions of Neurology and Clinical/Metabolic Genetics (GY), Division of Molecular Genetics (PNR), DPLM, The Hospital for Sick Children, University of Toronto, Toronto; Department of Paediatrics (RGS), Queen's University, Hotel Dieu Hospital, Kingston; ON, Canada.

RECEIVED SEPTEMBER 30, 2010. FINAL REVISIONS SUBMITTED NOVEMBER 19, 2010.

Correspondence to: Jean K. Mah, Alberta Children's Hospital, 2888 Shaganappi Trail NW, Calgary, Alberta, T3B 6A8, Canada.

Duchenne and Becker muscular dystrophy (DBMD) are X-linked recessive allelic disorders caused by mutations of the *dystrophin* gene on Xp21. Duchenne muscular dystrophy (OMIM #310200) is the most common form of muscular dystrophy in childhood, with an incidence of 1 in 3,500 boys¹. The absence or alteration of the dystrophin protein leads to calf pseudohypertrophy, muscle weakness, joint contractures, and cardiorespiratory dysfunction. Motor developmental delay, proximal weakness, and a variable degree of cognitive impairment are common presenting complaints. Duchenne muscular dystrophy (DMD) is associated with a severe phenotype, whereas Becker muscular dystrophy (BMD, OMIM #300376) is a generally milder and more variable form of muscular dystrophy. Among individuals with DMD, progressive muscle necrosis leads to loss of independent ambulation by early adolescence, scoliosis, cardiomyopathy, respiratory insufficiency, and premature death as early as the third decade of life. The diagnosis of dystrophinopathy is usually considered after careful review of the clinical features, family history, laboratory evidence of markedly elevated serum creatine kinase (CK), and confirmed by investigations including muscle biopsy or molecular genetic testing.

The *dystrophin* gene contains 79 exons, which includes an actin-binding domain at the N-terminus, 24 spectrin-like repeat units, a cysteine-rich dystroglycan binding site, and a C-terminal domain^{2,3}. Two-thirds of dystrophin mutations are inherited; the remaining one-third occurs as *de novo* mutations⁴. The extremely large size of the *dystrophin* gene (2.4 Mb) results in a complex mutational spectrum (>5000 different reported mutations in the Leiden muscular dystrophy database, available via www.dmd.nl) as well as a high spontaneous mutation rate⁵. The primary objective of this study was to describe the changes in diagnostic testing for dystrophinopathy from 2000 to 2009 and to determine the frequency of *dystrophin* gene mutations among patients followed at participating Canadian Paediatric Neuromuscular Group (CPNG) centers during the same period.




Figure 1: Total number of dystrophinopathy cases across Canada from 2000 to 2009.

METHODS

The CPNG includes neurologists, physiatrists, geneticists, and paediatricians across Canada who follow children with neuromuscular diseases in a tertiary care paediatric hospital or rehabilitative centre. The CPNG was established in 2005 as a collaborative effort to promote research and to enhance the clinical care of children with neuromuscular diseases. Informed consent was obtained for molecular genetic analysis, and the study was approved by the University of Calgary Conjoint Health Research and Ethics Board. De-identified data consisting of the clinical phenotypes, diagnostic methods, and molecular genetic reports from DBMD patients followed by participating CPNG centres from January 2000 to December 2009 were collected and verified at the Hospital for Sick Children in Toronto. The Molecular Genetics Laboratory at The Hospital for Sick Children is the only accredited laboratory in Canada for *dystrophin* DNA sequencing. Results were summarized using descriptive statistics and analyzed using Stata version 9.0 (StataCorp, College Station, TX) statistical software. Categorical variables were expressed as frequencies and percentages. Continuous variables were reported as means with standard deviations (SD) or as medians with interquartile ranges if the data were skewed. Bivariate comparisons were made using Pearson's chi-square or Fisher's exact tests for categorical variables and unpaired Student's t-tests or one-way analyses of variance for continuous variables. All tests were two-tailed, and p values less than 0.05 were considered to be statistically significant.

RESULTS

a. Phenotypic presentation

There were 773 individuals with dystrophinopathy, including 529 (68%) with DMD and 137 (18%) with BMD phenotype.



Figure 2: Estimated prevalence of dystrophinopathy per 10,000 males across Canada.

One hundred and seven (14%) had an unspecified phenotype due to young age at time of diagnosis, lack of follow-up, and/or insufficient clinical details to allow differentiation between DMD and BMD. Most (97%) of the 773 patients had a confirmed diagnosis of dystrophinopathy based on molecular genetic testing, including multiplex ligation-dependent probe amplification (MLPA) in 439 (57%) cases, multiplex polymerase chain reaction (PCR) in 168 (22%) cases, and sequencing of the entire dystrophin gene in 142 (18%). The remaining 24 cases were confirmed based on muscle biopsy (2%) or positive family history in the setting of typical clinical features for DMD or BMD (1%) and a markedly elevated serum CK.

b. Distribution of cases and estimated prevalence

The average number of DBMD cases was 72 per year (SD: 25) (see Figure 1). There was a gradual increase in the number of reported DBMD cases over time, with a significant difference between year 2000-2004 (mean 53, SD 9) and year 2005-2009 (mean 91, SD 20, unpaired Student's T-test $p = 0.009$). Using the Canadian 2006 census data of 31,612,897 people (including 15,475,970 males and 16,136,927 females) as the mean population for the ten year period from 2000 to 2009, the estimated prevalence of dystrophinopathy across Canada was 773/5,000,555, or 1.5 per 10,000 males between the ages of 0 to 24 years (95% confidence interval, CI, 1.2 - 1.9). The estimated prevalence for each province is summarized in Figure 2. There was no significant difference in the prevalence of dystrophinopathy among the provinces.

c. Common mutation sites

Five hundred and seventy three (74%) subjects including 377 DMD, 105 BMD, and 91 with unspecified phenotype had complete analysis of all 79 exons or whole gene sequencing, resulting in 366 (64%) deletions, 64 (11%) duplications, and 143 (25%) point mutations. Seven out of the ten most common deletions from this study were identical to those reported by White et al from the Leiden DMD mutation database⁶; in contrast, only three out of the top ten duplications were shared by the Leiden database (see Supplementary Table 1).

Among the 366 individuals with confirmed deletions involving one or more exons, a major mutational hotspot around exons 45 to 55 was found. The ten most common deletions (147 out of 366, approximately 40%) reported in this study were exons 45 – 47 (n=27, 7%), 45 – 48 (n=17, 5%), 45 (n=15, 4%), 45 – 50 (n=15, 4%), 45 – 55 (n=14, 4%), 51 (n=12, 3%), 45 – 49 (n=12, 3%), 45 – 52 (n=12, 3%), 49 – 50 (n=12, 3%), and 46 – 47 (n=11, 3%) (see Figure 3).

Among the 64 individuals with confirmed duplications involving one or more exons, a minor mutational hotspot around exons 2 to 20 was noted (see Figure 4). The most common duplications (29 out of 64, approximately 45%) were exons 2 (n=13, 20%), 2 – 7 (n=2, 3%), 2 – 17 (n=2, 3%), 3 – 7 (n=2, 3%), 8 – 11 (n=2, 3%), 10 (n=2, 3%), 10 – 11 (n=2, 3%), 12 (n=2, 3%), 63 – 69 (n=2, 3%), and 64 – 67 (n=2, 3%). The reason for the increased mutagenic susceptibility around the major (exons 45 – 55) and minor (exons 2 – 20) hotspot regions remains unclear.

Supplementary Table 1: Most common deletions and duplications across Canada, as compared with White et al [2006]*

RANK	Deletion (current study)	Deletion (White et al)	Duplication (current study)	Duplication (White et al)
1	45-47	45-47	2	2
2	45-48	45	2-7	2-7
3	45	48-50	2-17	8-9
4	45-50	45-48	3-7	3-7
5	45-55	45-50	8-11	51
6	51	51	10	3-4
7	45-49	44	10-11	44
8	45-52	49-50	12	8-13
9	49-50	3-7	63-69	2-11
10	46-47	45-52	64-67	3-11

*Common mutations are highlighted in bold




Figure 3: Confirmed deletions of the dystrophin gene among CPNG centers

Among the 143 cases with point mutations, 67 (47%) had nonsense mutations, 43 (30%) had point deletions, and 33 (23%) had small substitutions, duplications and insertions. In contrast to deletions or duplications involving one or more exons, point mutations were detected throughout the *dystrophin* gene, with no specific regions prone to increased mutation rates (see Supplementary Table 2).

d. Correlation with clinical phenotypes

We examined cases with confirmed boundaries of deletions or duplications to determine if the changes resulted in either an out-of-frame or in-frame mutation. According to the reading frame rule⁵, an out-of-frame mutation is associated with a DMD phenotype, with inability to walk unsupported by 12 to 14 years-of-age and/or evidence of absent dystrophin on muscle biopsy. An in-frame mutation is associated with a milder BMD phenotype, with ability to walk unassisted beyond 16 years-of-age and/or reduced dystrophin by immunohistochemistry. We found that a number of identical deletions or duplications involving one or more exons were reportedly associated with both a severe DMD as well as a milder BMD phenotype. These deletions and effects of the mutations using the Leiden DMD

gene reading frame checker (www.dmd.nl/index.html) were: exons 3 – 7, an out-of-frame deletion (4 DMD, 4 BMD); 3 – 11, an out-of-frame deletion (1 DMD, 1 BMD); 45 – 47, an in-frame deletion (5 DMD, 21 BMD); 45 – 49, an in-frame deletion (5 DMD, 6 BMD); 45 – 51, an in-frame deletion (1 DMD, 1 BMD); 45 – 53, an in-frame deletion (1 DMD, 6 BMD); and 45 – 55, an in-frame deletion (1 DMD, 12 BMD) (see Supplementary Table 3). The only duplication reportedly associated with 10 DMD as well as 1 BMD phenotype was exon 2, an out-of-frame mutation (see Supplementary Table 4). In total, at least 13 DMD cases had an in-frame deletion, whereas six BMD cases possessed an out-of-frame deletion. The variable phenotypes may be related in part to known exceptions to the reading frame rule, which has been reported in up 10% of *dystrophin* gene mutations with either deletions or duplications⁵.

The majority of the 67 cases with nonsense mutations were reportedly associated with a DMD phenotype, except for a premature stop codon mutation in exon 38 (c.5404C>T (Q1802X)) in two subjects that was associated with a milder BMD phenotype (see Supplementary Table 2). Only one nonsense mutation involving exon 60 (c.8944C>T (p.R2982X)) was reportedly shared by two brothers.




Figure 4: Confirmed duplications of the dystrophin gene among CPNG centers

Supplementary Table 2: Confirmed point mutations among Canadian sites*

Exon	Type	Report	Phenotype	Exon	Type	Report	Phenotype
2	Pt-del	c.53delA (p.Lys18Argfs)	BMD	20	Pt-stop	c.2440G>T (p.Glu814X)	MD
6	Pt-del	c.367_368delGT	MD	21	Pt-stop	c.2665C>T (p.Arg889X)	DMD
8	Pt-del	c.676_678delAAG (p.K226del)	BMD	21	Pt-stop	c.2677C>T (p.Gln893X)	DMD
10	Pt-del	c.1134delG	DMD	23	Pt-stop	c.3151C>T (p.Arg1051X)	DMD
12	Pt-del	c.1390delC	DMD	24	Pt-stop	c.3256A>T (p.K1086X)	DMD
14	Pt-del	c.1666delG	MD	25	Pt-stop	c.3414G>A (p.Trp1138X)	DMD
15	Pt-del	c.1784_1788del (p.Glu595fs)	DMD	27	Pt-stop	c.3625C>T (p.Gln1209X)	DMD
15	Pt-del	c.1784_1788delAAATG (p.Glu595fs)	MD	32	Pt-stop	c.4375C>T (p.R1459X)	DMD
16	Pt-del	c.1943delC	DMD	32	Pt-stop	c.4483C>T (p.Gln1495X)	DMD
18	Pt-del	c.2183_2184delTA (p.Ile728fs)	DMD	33	Pt-stop	c.4666G>T (p.Gly1556X)	DMD
18	Pt-del	c.2183_2184delTA (p.Ile728fs)	DMD	34	Pt-stop	c.4729C>T (p.Arg1577X)	DMD
18	Pt-del	c.2281_2285del (p.Glu761fs)	MD	34	Pt-stop	c.4814G>T (p.Q1536X)	DMD
18	Pt-del	c.2281_2285del (p.Glu761fs)	DMD	36	Pt-stop	c.5131C>T (p.Gln1711X)	DMD
20	Pt-del	c.2384delG	MD	36	Pt-stop	c.5131C>T (p.Gln1711X)	DMD
21	Pt-del	c.2636_2654del (p.Arg879fs)	DMD	37	Pt-stop	c.5159T>G (p.Leu1720X)	DMD
24	Pt-del	c.3179delT (p.Leu1060fs)	DMD	38	Pt-stop	c.5404C>T (p.Q1802X)	BMD
26	Pt-del	c.3347_3350delAGAA	DMD	38	Pt-stop	c.5404C>T (p.Q1802X)	BMD
27	Pt-del	c.3737_3743del (p.Asn1246fs)	DMD	39	Pt-stop	c.5521G>T (p.Glu1841X)	BMD
29	Pt-del	c.3963delT (p.Asn1321fs)	MD	39	Pt-stop	c.5495C>T (p.R1763X)	MD
30	Pt-del	c.4156delC (p.Leu1386fs)	DMD	41	Pt-stop	c.5878G>T (p.Glu1960X)	MD
35	Pt-del	c.4876_4887del (p.Val1625_Lys1629del)	BMD	41	Pt-stop	c.5878G>T (p.Glu1960X)	DMD
35	Pt-del	c.4876_4887del (p.Val1625_Lys1629del)	BMD	41	Pt-stop	c.5878G>T (p.Glu1960X)	DMD
36	Pt-del	c.5118_5119delGA (p.Lys1708GlufsX9)	DMD	42	Pt-stop	c.5938G>T (p.Glu1980X)	DMD
38	Pt-del	c.5401_5402delAT	DMD	43	Pt-stop	c.6250C>T (p.Gln2084X)	MD
38	Pt-del	c.5447delT (p.Met1812fs)	MD	45	Pt-stop	c.6460C>T (p.Gln2154X)	DMD
39	Pt-del	c.5475delA	DMD	47	Pt-stop	c.6905G>A (p.Trp2303X)	DMD
47	Pt-del	c.6804_6807del	DMD	52	Pt-stop	c.7561G>T (p.E2521X)	DMD
47	Pt-del	c.6809del4bp	DMD	54	Pt-stop	c.8009G>A (p.W2670X)	DMD
50	Pt-del	c.7292_7296del	DMD	55	Pt-stop	c.8161A>T (p.Lys2721X)	DMD
55	Pt-del	c.8167delA	DMD	55	Pt-stop	c.8214G>A (p.W2738X)	DMD
57	Pt-del	c.8542delC (p.His2848fs)	DMD	57	Pt-stop	c.8464C>T (p.Gln2822X)	DMD
58	Pt-del	c.8605_8606del (p.Val2869fs)	DMD	57	Pt-stop	c.8483T>G (p.L2828X)	DMD
59	Pt-del	c.8912_8913del (p.Leu2971fs)	DMD	60	Pt-stop	c.8944C>T (p.R2982X)	DMD
65	Pt-del	c.9556del; 9562_9563+13del	DMD	60	Pt-stop	c.8944C>T (p.R2982X)	DMD
66	Pt-del	c.9596_9597delTT	MD	60	Pt-stop	c.9001C>T (p.Gln3002X)	DMD
68	Pt-del	c.9854_9863del (p.Leu3329X)	DMD	61	Pt-stop	c.9100C>T (p.Arg3034X)	DMD
70	Pt-del	c.10101_10103del (p.Glu3367del)	DMD	61	Pt-stop	c.9100C>T (p.Arg3034X)	DMD
74	Pt-del	c.10441delC (p.Gln3481fs)	DMD	61	Pt-stop	c.9100C>T (p.Arg3034X)	DMD
74	Pt-del	c.10454delT (p.Leu3485Argfs)	DMD	63	Pt-stop	c.9276C>A (p.Y3092X)	DMD
74	Pt-del	c.10454delT (p.Leu3485fs)	MD	67	Pt-stop	c.9661C>T (p.Gln3221X)	MD
74	Pt-del	c.10454delT (p.Leu3485fs)	MD	68	Pt-stop	c.9851G>A (p.W3284X)	DMD
74	Pt-del	c.10454delT (p.Leu3485fs)	DMD	70	Pt-stop	c.10108C>T (p.Arg3370X)	DMD
75	Pt-del	c.10744delC (p.His3582fs)	DMD	70	Pt-stop	c.10108C>T (R3370X)	DMD
26	Pt-delins	c.3494_3497delATCTinsCCTTCGTGTC	DMD	70	Pt-stop	c.10171C>T (R3391X)	DMD
66	Pt-delins	c.9564-1_9564delinsTT [r.(spl?)]	DMD	70	Pt-stop	c.10171C>T (R3391X)	DMD
17	Pt-dup	c.2044dupA	DMD	5	Pt-sub	c.265-1G>C	DMD
27	Pt-dup	c.3713dupA (p.Glu1239fs)	MD	5	Pt-sub	c.265-2A>G	DMD
63	Pt-dup	c.9260_9278dup	DMD	5	Pt-sub	c.357+1G>T [r.(spl)]	MD
27	Pt-inser	c.3705_3706ins11	MD	6	Pt-sub	c.511G>C (p.Alal71Pro)	BMD
62	Pt-inser	c.9221_9222insAT	DMD	7	Pt-sub	c.649+1G>T	DMD
43	Pt-inser	c.6290_6291ins80bp	DMD	7	Pt-sub	c.649+1G>T	DMD
5	Pt-stop	c.355C>T (p.Q119X)	DMD	7	Pt-sub	c.531-1G>C	DMD
6	Pt-stop	c.433C>T (p.R145X)	DMD	7	Pt-sub	c.649+2T>C	DMD
8	Pt-stop	c.783dupT (p.Lys262X)	DMD	9	Pt-sub	c.961-1G>A [r.(spl?)]	DMD
8	Pt-stop	c.829C>T (p.Gln277X)	DMD	13	Pt-sub	c.1483-2A>C	BMD
8	Pt-stop	c.799C>T (p.Q267X)	DMD	13	Pt-sub	c.1483-1G>C	BMD
11	Pt-stop	c.1292G>A (p.Trp431X)	DMD	16	Pt-sub	c.1992+2T>G	DMD
11	Pt-stop	c.1207G>T (p.Gly403X)	DMD	18	Pt-sub	c.2292+2T>C	DMD
12	Pt-stop	c.1357C>T (p.Gln453X)	DMD	26	Pt-sub	c.3603+3A>T	BMD
14	Pt-stop	c.1615C>T (p.Arg539X)	DMD	26	Pt-sub	c.3603+3A>T	BMD
14	Pt-stop	c.1637G>A (p.Trp546X)	MD	48	Pt-sub	c.7096A>C (p.K2366Q)	DMD
14	Pt-stop	c.1637G>A (p.Trp546X)	DMD	52	Pt-sub	c.7571G>A (p.Arg2524His)	MD
14	Pt-stop	c.1702C>T (p.Q568X)	DMD	56	Pt-sub	c.8218-2A>G	DMD
16	Pt-stop	c.1990C>T (p.Gln664X)	DMD	56	Pt-sub	c.8218-2A>G	DMD
18	Pt-stop	c.2276_2292+70delins40bp	DMD	59	Pt-sub	c.8729A>T (p.Glu2910Val); c.8734A>G (p.Asn2912Asp)	DMD
18	Pt-stop	c.2276_2292+70delins40bp	DMD	64	Pt-sub	c.9361+1G>A	DMD
19	Pt-stop	c.2302C>T (p.R798X)	DMD	68	Pt-sub	c.9974+3A>T	BMD
19	Pt-stop	c.2302C>T (p.Arg768X)	DMD	68	Pt-sub	c.9937T>G (p.C3313G)	MD
19	Pt-stop	c.2353C>T (p.Gln785X)	DMD	69	Pt-sub	c.9975-2A>G	DMD
19	Pt-stop	c.2332C>T (p.Gln778X)	DMD	69	Pt-sub	c.9975-2A>G	MD
19	Pt-stop	c.2332C>T (p.Gln778X)	DMD				

* Identical mutations shared by two or more individuals are highlighted in grey; DMD refers to Duchenne muscular dystrophy, BMD refers to Becker muscular dystrophy, and MD denotes an unspecified phenotype.

e. Change in diagnostic approaches over time

Only 13 (2%) of all dystrophinopathy cases were diagnosed based on muscle biopsy alone, and they were performed at or before the year 2000. The muscle biopsy criteria for the diagnosis of DBMD was based on the pathological features of a dystrophic process with diffuse variation in fiber size, necrosis, and fibrosis, plus either absent (DMD) or reduced (BMD) dystrophin by immunohistochemistry. As seen in Figure 5, there was a noticeable change in the molecular diagnostic methods

over time. Multiplex polymerase chain reactions (PCR) of a subset of exons was the most common diagnostic test initially (up to 98% of cases) in 2000, but it was gradually replaced by MLPA and other molecular genetic tests that interrogated all 79 exons. Overall, MLPA confirmed the mutations in 431 (75%) cases. Complete gene sequencing was introduced in 2002, and it was used in 142 cases (25%) between 2002 to 2009 if MLPA failed to detect a deletion or duplication in the *dystrophin* gene.

Supplementary Table 3: Confirmed deletions among CPNG sites*

Exons	Frequency	Phenotypes	Exons	Frequency	Phenotypes
1	4	DMD (2), MD (2)	43	4	DMD
2-7	4	BMD	44	10	DMD (9), MD (1)
3-4	6	BMD (5), MD (1)	44-51	1	DMD
3-7	8	DMD (4), BMD (4)	44-52	1	DMD
3-9	1	MD	45	15	DMD
3-11	3	DMD (1), BMD (1), MD (1)	45-46	1	DMD
3-13	4	DMD (3), MD (1)	45-47	27	BMD (21), DMD (5), MD (1)
3-17	3	DMD	45-48	17	BMD (15), MD (2)
3-19	1	DMD	45-49	12	BMD (6), DMD (5), MD (1)
3-43	2	MD	45-50	15	DMD (11), MD (4)
3-44	1	DMD	45-51	2	BMD (1), DMD (1)
4	1	BMD	45-52	12	DMD (10), MD (2)
4-7	1	BMD	45-53	10	BMD (6), DMD (1), MD (3)
5	1	BMD	45-55	14	BMD (12), DMD (1), MD (1)
5-9	1	MD	46	3	DMD
5-13	2	DMD	46-47	11	DMD (9), MD (2)
5-16	1	BMD	46-48	3	DMD (2), MD (1)
5-19	1	DMD	46-49	2	DMD
6-14	1	DMD	46-50	3	DMD (1), MD (2)
6-41	1	DMD	46-51	5	DMD (4), MD (1)
7	1	DMD	46-52	6	DMD (5), MD (1)
8	1	DMD	46-53	1	DMD
8-9	1	DMD	46-55	2	DMD
8-11	2	DMD	47-48	1	BMD
8-12	1	DMD	47-50	1	DMD
8-37	1	MD	48	3	DMD
8-42	1	DMD	48-49	4	BMD (2), MD (2)
8-47	1	MD	48-50	7	DMD (2), MD (5)
10-11	2	DMD	48-51	1	BMD
10-17	1	DMD	48-52	4	DMD
12-13	1	DMD	49-50	12	DMD (10), MD (2)
12-21	1	DMD	49-51	2	DMD (1), MD (1)
12-29	1	DMD	49-52	5	DMD (3), MD (2)
12-34	1	DMD	49-54	1	DMD
13-17	1	DMD	50	2	DMD
13-43	1	DMD	50-52	1	DMD
13-47	1	DMD	51	12	DMD (10), MD (2)
13-53	1	MD	51-53	2	DMD (1), MD (1)
14-19	2	DMD (1), MD (1)	51-54	1	DMD
14-39	1	BMD	51-55	1	DMD
14-40	1	BMD	52	9	DMD
14-41	2	BMD (1), MD (1)	53	2	DMD
17	1	DMD	53-54	2	DMD
17-43	1	DMD	53-55	4	DMD
18	1	DMD	53-57	1	DMD
19	1	MD	55	1	DMD
19-51	1	DMD	56	2	DMD
21	1	DMD	56-62	1	DMD
22	1	DMD	61	2	DMD
22-23	1	DMD	63-78	2	DMD
22-24	1	MD	63-79	2	DMD
22-26	1	DMD	64-67	1	MD
22-34	1	DMD	64-78	1	DMD
22-38	1	DMD	65-67	1	DMD
30-50	1	MD	68-70	1	MD
31-43	1	DMD	68-71	1	DMD
34-44	1	DMD	Total	366	
35-43	1	DMD			
36-43	1	DMD			
38-43	2	DMD			
42-43	4	DMD (3), MD (1)			

* Identical mutations with both Duchenne (DMD) and Becker (BMD) muscular dystrophy phenotypes are highlighted in grey; MD denotes an unspecified phenotype.

f. Variability in access to complete genetic testing across the provinces

Patients were considered to have had complete genetic testing if all 79 exons of the *dystrophin* gene were examined and if this was negative, complete sequencing of the gene was performed. Diagnosis made solely by muscle biopsy or multiplex PCR analysis of a subset of exons was considered incomplete genetic testing. The national mean percentage of dystrophinopathy cases diagnosed by complete genetic testing was 63% (SD 23). Alberta

(AB) and Newfoundland (NL) were close to the national mean, with complete genetic testing rates of 63% and 61% respectively (see Supplementary Figure 1). There was a significant difference among the provinces, with the lowest rates (mean 42, SD 6) of complete genetic testing reported in Nova Scotia (NS), Manitoba (MB), and British Columbia (BC). In contrast, the provinces of Ontario (ON), Saskatchewan (SK) and Quebec (QC) had the highest completion rates (mean 83, SD 7, t-test $p=0.0018$). Provinces with the lowest rates of complete genetic testing (NS,




Figure 5: Change in diagnostic methods for dystrophinopathy from 2000 to 2009. PCR denotes multiplex polymerase chain reaction of subset of exons, MLPA refers to multiple ligation-probe amplification of all 79 exons, and SEQUENCE represents dystrophin gene sequencing.

MB, BC) had relied more on multiplex PCR analysis for a subset of exons (61%, 59%, and 47%) and less on complete gene sequencing (17%, 15%, and 7.2% respectively) for diagnosis. Overall, close to one-quarter (168/773 cases, 22%) of Canadian dystro-phinopathy patients were diagnosed based on multiplex PCR analysis of the *dystrophin* gene without supplementary testing. Among the 200 cases with incomplete genetic testing, the phenotypes included 153 DMD, 32 BMD, and 15 cases of unspecified dystrophinopathy.

DISCUSSION

We found an estimated prevalence of dystrophinopathy of 1.5 per 10,000 males in Canada. According to Emery, the incidence of DMD was 2.9 per 10,000, while BMD was 0.5 per 10,000¹. In other reports, the incidence of DMD ranged from 1 in 7,730 (1.3 per 10,000) to 1 in 3,871 (2.6 per 10,000) by newborn screening in the United Kingdom⁷, and 1 per 4,700 (2.1 per 10,000) through a regional clinic in Nova Scotia⁸. A 2007 survey in the United States showed an overall prevalence of 1.3 to 1.8 per 10,000⁹. Results from our population-based study of the prevalence of dystrophinopathy in Canada appeared to be similar to these published reports. Consistent with two previous Canadian studies of smaller sample sizes^{10,11}, deletions of one or more exons accounted for the majority (n=366, 64%) of the mutations. Another 63 (11%) individuals had duplications and 144 (25%) had point mutations. The proportion of deletions, duplications, and point mutations was similar to other recent reports on dystrophinopathy^{6,12,13}.

Over the past decade, there have been considerable advances in the diagnostic approach to dystrophinopathy. Until 1988, the diagnosis usually required an open muscle biopsy, which is an invasive procedure that can be associated with bleeding, infection, and other potentially serious complications. In the





Figure 6: Recommended diagnostic approach to dystrophinopathy in Canada.

early 1990s, multiplex polymerase chain reaction provided a simple, rapid, and efficient alternative to identify common deletions occurring at one of two regions or mutational “hot-spots” such as exons 2 – 20 and 44 – 53¹⁴. Additional multiplex primer sets were added to extend the previously untested regions¹⁵⁻¹⁷. Although common deletions can be detected using multiplex PCR, only selective exons are examined, and precise deletion borders cannot be confirmed. In addition, duplications and small mutations will be missed. Therefore, diagnostic methods such as Southern blotting, Multiplex Amplifiable Probe Hybridization (MAPH)¹⁸, Multiplex Ligation-dependent Probe Amplification¹⁹, other quantitative multiplex PCR assays¹¹, whole gene sequencing, and more recently Comparative Genomic Hybridization (CGH) microarray²⁰ are employed to detect deletions and duplications in all 79 exons.



Supplementary Figure 1: Percentage of dystrophin mutation completion rates across eight Canadian provinces. NS, Nova Scotia; MB, Manitoba; BC, British Columbia; NL, Newfoundland; AB, Alberta; QC, Quebec; SK, Saskatchewan; ON, Ontario.

Supplementary Table 4: Confirmed duplications among Canadian sites*

Exons	Frequency	Phenotypes
1-7	1	DMD
2	13	DMD (10), BMD (1), MD (2)
2-3	1	MD (1)
2-7	2	BMD
2-13	1	DMD
2-17	2	DMD (1), MD (1)
3	1	MD
3-4	1	BMD
3-5	1	DMD
3-7	2	DMD
3-9	1	DMD
3-11	1	DMD
3-13	1	BMD
3-17	1	DMD
4-15	1	DMD
5-10	1	DMD
5-25	1	BMD
8-11	2	DMD (1), MD (1)
8-25	1	MD
8-32	1	MD
9	1	MD
10	2	DMD
10-11	2	DMD
10-17	1	DMD
12	2	DMD
12-27	1	DMD
13-29	1	MD
14-21	1	DMD
26-43	1	DMD
31-54	1	DMD
40-43	1	DMD
44	1	DMD
45	1	DMD
45-54	1	DMD
45-60	1	DMD
48-65	1	DMD
49-55	1	DMD
50	1	DMD
51-52	1	DMD
56-62	1	DMD
62	1	DMD
63-69	2	DMD
64-67	2	DMD
Total	64	

*Identical mutation with both Duchenne (DMD) and Becker (BMD) muscular dystrophy phenotypes is highlighted in grey; MD denotes an unspecified phenotype.

Currently MLPA is the initial diagnostic method that is widely available across Canada for individuals with suspected dystrophinopathy. Those with negative MLPA or other quantitative PCR assays should have whole gene sequencing to identify point mutations and sequence variations in the *dystrophin* gene (see Figure 6)²¹. Approximately 1 to 2% of individuals with dystrophinopathy will not have an identifiable mutation based on gene sequencing. Muscle biopsy can then be performed to confirm the diagnosis by immunohistochemistry and/or Western blot analysis to detect the absence or alteration in the dystrophin protein. Dystrophin messenger ribonucleic acid (mRNA) can also be extracted from the muscle biopsy to determine the precise copy deoxyribonucleic acid (cDNA) sequence, including those with “identical” deletion or duplication that can occasionally produce either a DMD or a BMD phenotype due to different intronic breakpoints that affect gene splicing. Using all available diagnostic methods, it is possible to identify the *dystrophin* mutations and confirm the clinical phenotypes in nearly all patients with dystrophinopathy^{22,23}.

Identification of a specific *dystrophin* mutation is important for accurate diagnosis, prognosis, and treatment for patients with DBMD, as well as genetic counseling for their families, which is routinely offered at all CPNG centers²⁴. According to our study, only 74% of Canadian patients were diagnosed by currently acceptable genetic testing methods, and the same mutation completion rate (74%) was reported by the Muscular Dystrophy Surveillance Tracking and Research Network in the United States last year²⁵. Potential reasons for the variability in rates of diagnosis based on complete genetic testing across Canada include: a) lack of availability of *dystrophin* gene sequencing in most provinces; b) challenges related to obtaining funding approval to pay for out-of-province genetic testing, including *dystrophin* gene sequencing; c) lack of awareness regarding the potential benefits of precise mutation analysis by patients, families, or health care professionals; and d) reliance on multiplex PCR or muscle biopsy for diagnosis instead of *dystrophin* gene sequencing to detect point mutations by the treating physicians. This is an area that will require further investigation and is beyond the scope of our study. Other potential limitations of this study included an inability to include full clinical information due to privacy restrictions when reviewing genetic database, and the clinical phenotypes were determined by retrospective chart reviews but were not verified over time. As well, since not all CPNG members participated in this study, there may be additional patients with dystrophinopathy who were not included as they were either: a) seen elsewhere in Canada, including BMD patients followed in adult centers; b) had genetic testing through facilities in the United States or other private clinics, c) lost to follow-up, or d) died during the study period.

CONCLUSIONS

Recent scientific advances have led to potentially novel treatments for dystrophinopathy that are highly genotype specific, including: a) nonsense suppression therapy with small molecule drugs such as PTC124 or gentamicin which aims to increase ribosomal read through of premature stop codon during translation to produce a modified dystrophin protein^{26,27}; and b) exon-skipping with synthetic antisense oligonucleotide sequences to correct the reading frame shift by ‘skipping over’ specific exons and producing an internally truncated protein^{28,29}. Most upcoming clinical trials for dystrophinopathy will require precise genetic and phenotypic confirmation prior to study enrollment. Dystrophin gene sequencing should therefore be readily available to all patients across Canada when MLPA testing has been uninformative. The success of novel therapeutic strategies for DBMD will ultimately depend on accurate clinical assessment and mutational analysis in potential subjects, the creation of a national or global disease-specific patient registries for comprehensive diagnosis and clinical trials readiness, and on-going interdisciplinary collaboration among academic centers to ensure that all Canadians with dystrophinopathy are eligible to receive optimal care and gain access to mutation-specific therapies.

ACKNOWLEDGEMENT

The authors thank other CPNG members and colleagues for their support of this project: Dr. Brenda Banwell, The Hospital for Sick Children, Toronto, Ontario; Dr. Doug Biggar, Bloorview Kids Rehab, Toronto, Ontario; Dr. Peter Bridge, Alberta Children's Hospital, Calgary, Alberta; Dr. Renée-Myriam Boucher, University of Laval, Quebec City, Quebec; Dr. Gillian Hogan, Erin Oak Children's Center, Mississauga, Ontario; Dr. Noel Lowry, University of Saskatchewan, Saskatoon, Saskatchewan; Dr. Laura McAdam, Bloorview Kids Rehab, Toronto, Ontario; Dr. Hugh McMillan, Children's Hospital of Eastern Ontario, Ottawa, Ontario; Dr. David Meek, St. John's Regional Hospital, St. John's, Newfoundland; Dr. Chantal Poulin, Montreal Children's Hospital, Montreal, Quebec; Dr. Bev Prieur, Alberta Children's Hospital, Calgary, Alberta; and Dr. Jiri Vasjar, The Hospital for Sick Children, Toronto, Ontario.

REFERENCES

- Emery AE. Population frequencies of inherited neuromuscular diseases—a world survey. *Neuromuscul Disord.* 1991;1(1):19-29.
- Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. *Cell.* 1987; 51(6):919-28.
- Koenig M, Monaco AP, Kunkel LM. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. *Cell.* 1988;53(2):219-28.
- Laing NG. Molecular genetics and genetic counselling for Duchenne/Becker muscular dystrophy. In: Partridge TA, editor. *Molecular and cell biology of muscular dystrophy.* London: Chapman & Hall; 1993. p. 37-84.
- Aartsma-Rus A, Van Deutekom JC, Fokkema IF, Van Ommen GJ, Den Dunnen JT. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. *Muscle Nerve.* 2006;34(2):135-44.
- White SJ, den Dunnen JT. Copy number variation in the genome; the human DMD gene as an example. *Cytogenet Genome Res.* 2006;115(3-4):240-6.
- Bradley D, Parson E. Newborn screening for Duchenne muscular dystrophy. *Semin Neonatol.* 1998;3:27-34.
- Dooley J, Gordon KE, Dodds L, MacSween J. Duchenne muscular dystrophy: a 30-year population-based incidence study. *Clin Pediatr (Phila).* 2010;49(2):177-9.
- Centers for Disease Control and Prevention (CDC). Prevalence of Duchenne/Becker muscular dystrophy among males aged 5-24 years - four states, 2007. *MMWR Morb Mortal Wkly Rep.* 2009; 58(40):1119-22.
- Gillard EF, Chamberlain JS, Murphy EG, et al. Molecular and phenotypic analysis of patients with deletions within the deletion-rich region of the Duchenne muscular dystrophy (DMD) gene. *Am J Hum Genet.* 1989;45(4):507-20.
- Stockley TL, Akber S, Bulgin N, Ray PN. Strategy for comprehensive molecular testing for Duchenne and Becker muscular dystrophies. *Genet Test.* 2006;10(4):229-43.
- Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. *Lancet Neurol.* 2003;2(12):731-40.
- Yan J, Feng J, Buzin CH, et al. Three-tiered noninvasive diagnosis in 96% of patients with Duchenne muscular dystrophy (DMD). *Hum Mutat.* 2004;23(2):203-4.
- Chamberlain JS, Gibbs RA, Ranier JE, Nguyen PN, Caskey CT. Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification. *Nucleic Acids Res.* 1988;16 (23):11141-56.
- Towbin JA, Chamberlain JS, Wu DR, Pillers DA, Seltzer WK, McCabe ER. DXS28 (C7) maps centromeric to DXS68 (L1-4) and DXS67 (B24) by deletion analysis. *Genomics.* 1990;7(3): 442-4.
- Beggs AH, Koenig M, Boyce FM, Kunkel LM. Detection of 98% of DMD/BMD gene deletions by polymerase chain reaction. *Hum Genet.* 1990;86(1):45-8.
- Feener CA, Boyce FM, Kunkel LM. Rapid detection of CA polymorphisms in cloned DNA: application to the 5' region of the dystrophin gene. *Am J Hum Genet.* 1991;48(3):621-7.
- White S, Kalf M, Liu Q, et al. Comprehensive detection of genomic duplications and deletions in the DMD gene, by use of multiplex amplifiable probe hybridization. *Am J Hum Genet.* 2002;71(2): 365-74.
- Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. *Nucleic Acids Res.* 2002;30(12):e57.
- Hegde MR, Chin EL, Mülle JG, Okou DT, Warren ST, Zwick ME. Microarray-based mutation detection in the dystrophin gene. *Hum Mutat.* 2008;29(9):1091-9.
- Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. *Lancet Neurol.* 2010;9(1):77-93.
- Baskin B, Banwell B, Khater RA, Hawkins C, Ray PN. Becker muscular dystrophy caused by an intronic mutation reducing the efficiency of the splice donor site of intron 26 of the dystrophin gene. *Neuromuscul Disord.* 2009;19(3):189-92.
- Takeshima Y, Yagi M, Okizuka Y, et al. Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center. *J Hum Genet.* 2010;55 (6):379-88.
- McMillan HJ, Campbell C, Mah JK. Duchenne muscular dystrophy: Canadian paediatric neuromuscular physicians survey. *Can J Neurol Sci.* 2010;37(2):195-205.
- Cunniff C, Andrews J, Meaney FJ, et al. Mutation analysis in a population-based cohort of boys with Duchenne or Becker muscular dystrophy. *J Child Neurol.* 2009;24(4):425-30.
- Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. *Nature.* 2007;447 (7140):87-91.
- Malik V, Rodino-Klapac LR, Viollet L, et al. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. *Ann Neurol.* 2010;67(6):771-80.
- Muntoni F, Bushby K, van Ommen G. 128th ENMC international workshop on preclinical optimization and phase I/II clinical trials using antisense oligonucleotides in Duchenne muscular dystrophy, 22-24 October 2004, Naarden, the Netherlands. *Neuromuscul Disord.* 2005;15(6):450-7.
- van Deutekom JC, Janson AA, Ginjaar IB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. *N Engl J Med.* 2007;357(26):2677-86.